Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) Price & Performance

Citius Pharmaceuticals IncTrade
iShares S&P GSCI Commodity-Indexed Trust ETFTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs iShares S&P GSCI Commodity-Indexed Trust ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while iShares S&P GSCI Commodity-Indexed Trust ETF trades at $32.61. The key difference: iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

CTXRGSG
Market Cap
$20.01M
Sector
HealthCommodities - Metals/Agriculture
52-Week High
$1.82$34.77
52-Week Low
$0.48$22.06
Enterprise Value
$16.23M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.

While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.

iShares S&P GSCI Commodity-Indexed Trust ETF

GSG, the iShares S&P GSCI Commodity-Indexed Trust ETF, trades at $32.62, up 0.93% on the day, with technical indicators showing a bearish bias from moving averages but neutral oscillators. The ETF's performance is heavily tied to energy commodities, which drove strong gains in H1 2026, though recent analyst sentiment has turned cautious due to sector volatility. Key support is at $31, with resistance at $32.

The outlook for GSG hinges on commodity market dynamics, particularly energy prices, offering exposure to broad commodities but facing risks from geopolitical tensions and volatility. Investor caution is warranted as analysts highlight increased risks near current price levels, with a recent downgrade to Hold reflecting concerns over sustained outperformance.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About iShares S&P GSCI Commodity-Indexed Trust ETF

GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.

Read more on GSG